Company: GMRE
Filing Date: 2025-11-14
Form Type: 424B5
Source: 0001104659-25-112543
Chunk: 16

Company: Global Medical REIT Inc.
Filing Date: 2025-11-14
Form: 424B5
Chunk 16
---
 shares of
Series B Preferred Stock until we have paid or set aside for payment the full amount of the unpaid dividends on the shares that rank
in priority with respect to dividends that must, under the terms of such shares, be paid before we may pay dividends on, or redeem or
repurchase, the Series B Preferred Stock. In addition, in the event of any liquidation, dissolution or winding up of the Company,
holders of the Series B Preferred Stock will not be entitled to receive the liquidation preference of their shares until we have
paid or set aside an amount sufficient to pay in full the liquidation preference of any class or series of our capital stock ranking senior
as to rights upon liquidation, dissolution or winding up.

Other than the conversion right afforded to holders
of Series B Preferred Stock upon the occurrence of a Change of Control as described under “Description of Series B Preferred
Stock — Conversion Right upon a Change of Control” and other than the limited voting rights as described under “Description
of Series B Preferred Stock — Voting Rights,” none of the provisions relating to our Series B Preferred Stock relate
to or limit our indebtedness or afford the holders of our Series B Preferred Stock protection in the event of a highly leveraged
or other transaction, including a merger or the sale, lease or conveyance of all or substantially all of our assets or business, that
might adversely affect the holders of our Series B Preferred Stock.

Future offerings of debt or senior equity securities may adversely affect the market price of the Series B Preferred Stock.

If we decide to issue debt or senior equity securities
in the future, it is possible that these securities will be governed by an indenture or other instrument containing covenants restricting
our operating flexibility.

Additionally, any convertible or exchangeable
securities that we issue in the future may have rights, preferences and privileges more favorable than those of the Series B Preferred
Stock and may result in dilution to owners of the Series B Preferred Stock. We and, indirectly, our stockholders, will bear the cost
of issuing and servicing such securities. Because our decision to issue debt or equity securities in any future offering will depend on
market conditions and other factors beyond our control, we cannot predict or estimate the amount, timing or nature of our future offerings.
Thus holders of the Series B Preferred Stock will bear the risk of our future offerings reducing the market price of the Series B
Preferred Stock and diluting the value of their holdings in us.

<div align='center'>S-9